GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer Indications at AACR Annual Meeting 2015
"Our initial data supports further evaluation of our E-selectin-CXCR4
antagonist and its potential role in addressing a variety of cancers,
including those giving rise to bone metastases," said
The AACR posters from
-
"A Small Molecule Glycomimetic Antagonist of E-Selectin and CXCR4
(GMI-1359) Prevents Pancreatic Tumor Metastasis and Improves
Chemotherapy" [Tumor Biology: Cytokines and Chemokines and the
Microenvironment - Poster Session PO.TB06.01,
Sunday, April 19, 2015 ,1:00-5:00 p.m. Eastern Time ] Abstract 425 -
"Dual E-selectin and CXCR4 Inhibition Reduces Tumor Growth and
Increases the Sensitivity To Docetaxel in Experimental Bone Metastases
of Prostate Cancer" [Tumor Biology: Cytokines and Chemokines and the
Microenvironment - Poster Session PO.TB06.01,
Sunday, April 19, 2015 ,1:00-5:00 p.m. Eastern Time ] Abstract 428 -
"Metastatic Breast Cancer Cell Communication Within a Pro-dormancy
Bone Marrow Niche" [Tumor Biology: Dynamic Regulation of the Tumor
Microenvironment - Poster Session PO.TB06.08,
Tuesday, April 21, 2015 , times8:00-12:00 p.m. Eastern Time ] Abstract #3212
About
GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Pfizer is the company's development partner for rivipansel, a GlycoMimetics-discovered investigational therapy for pain crisis associated with sickle cell disease, and is preparing to conduct a Phase 3 clinical study. A GlycoMimetics wholly-owned candidate therapy (GMI-1271) for acute myeloid leukemia (AML) and other blood disorders is also in clinical trials. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Learn more at www.glycomimetics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding the
clinical development of GMI-1359 and of GMI-1271. Actual results may
differ materially from those in these forward-looking statements. For a
further description of the risks associated with these statements, as
well as other risks facing
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media